Breast Cancer Staging - Radiation Oncology

Front 1

T1

Back 1

2cm or less

Front 2

T1mi

Back 2

1mm or less (microinvasive)

Front 3

T1a

Back 3

>0.1 to 0.5cm

Front 4

T1b

Back 4

>0.5 to 1cm

Front 5

T1c

Back 5

>1cm to 2cm

Front 6

T2

Back 6

>2cm to 5cm

Front 7

T3

Back 7

> 5cm

Front 8

T4

Back 8

Chest wall/skin

Front 9

T4a

Back 9

chest wall (not including pectoralis muscle)

Front 10

T4b

Back 10

skin edema (peau d'orange), ulceration, or satellite skin nodules

Front 11

T4c

Back 11

both 4a and 4b

Front 12

T4d

Back 12

inflammatory carcinoma

Front 13

cN1

Back 13

movable ipsilateral axillary lymph nodes

Front 14

pN1mi

Back 14

micromets (> 0.2mm but <= 2.0mm)

Front 15

pN1a

Back 15

1-3 axillary lymph nodes (at least 1 >2.0mm)

Front 16

pN1b

Back 16

Metastases in IM nodes (micrometastases, or macrometastases detected by SLN biopsy but not clinically detected)

Front 17

pN1c

Back 17

1-3 axillary lymph nodes and metastases in IM nodes (micrometastases, or macromets detected by SLN but not clinically detected)

Front 18

cN2a

Back 18

Ipsilateral axillary lymph nodes fixed or matted

Front 19

pN2a

Back 19

4-9 axillary lymph nodes (at least 1 > 2.0 mm)

Front 20

cN2b

Back 20

Clinically detected internal mammary nodes in the absence of axillary lymph node metastases

Front 21

pN2b

Back 21

Metastases in clinically detected IM nodes in the absence of axillary lymph nodes

Front 22

cN3a

Back 22

Infraclavicular lymph nodes (level III)

Front 23

pN3a

Back 23

10 or more axillary lymph nodes (at least 1 > 2.0 mm); or infraclavicular (level III) lymph nodes

Front 24

cN3b

Back 24

Clinically apparent internal mammary nodes with axillary lymph node involvement

Front 25

pN3b

Back 25

Metastases in clinically detected IM nodes in the presence of positive axillary nodes; or microscopic IM nodes and more than 3 axillary lymph nodes

Front 26

cN3c

Back 26

Supraclavicular lymph nodes

Front 27

pN3c

Back 27

Supraclavicular lymph nodes

Front 28

"A" nodes are ...

Back 28

"A"xillary

Front 29

"B" nodes are ...

Back 29

internal "B"reast nodes (e.g. IMNs)

Front 30

"C" nodes are ...

Back 30

supra"C"lavicular excludes N1 subtype

Front 31

Stage IA

Back 31

T1N0

Front 32

Stage IB

Back 32

T0-1, N1mi

Front 33

Stage IIA

Back 33

T0-1 N1 or T2N0

Front 34

Stage IIB

Back 34

T2 N1 or T3 N0

Front 35

Stage IIIA

Back 35

T3 N1 or T0-3 N2

Front 36

Stage IIIB

Back 36

T4 N0-2

Front 37

Stage IIIC

Back 37

N3

Front 38

Stage IV

Back 38

M1

Front 39

changes from 6th edition:

Back 39

- T1mic changed to T1mi to indicate microscopic disease
- Clarification of wording of "not clinically detected" and "clinically detected" internal mammary nodes. *Clarification of Isolated tumor cells (ITC).
- Subdivision of Stage I into IA and IB (IB includes T0-T1 with N1mi nodal micrometastases). Otherwise, no changes in TNM or Overall Stage
- New cM0(i+) category for circulating tumor cells or incidentally discovered metastatic cells in other tissue
- Clarification of assigning staging after neoadjuvant therapy (yc or ypTNM)

Front 40

Luminal A type

Back 40

ER+ and/or PR+, HER2–. Usually low grade. These express genes similar to normal cells lining breast ducts and glands

Front 41

Luminal B type

Back 41

ER+ and/or PR+, HER2+. These are similar to luminal A, but grow faster and have a slightly poorer prognosis.

Front 42

Basal type

Back 42

ER–, PR–, HER2–, cytokeratin 5/6 positive, and/or HER1+. Also known as "triple negative". Higher prevalence in young African American women.

Front 43

HER2 type

Back 43

ER-, PR-, HER2+. Usually high histological grade.